| Sector |
Healthcare
|
Compare with Sector peers |
| Industry |
Hospital & Healthcare Services
|
Compare with Industry peers |
| Website | http://www.lalchandanipathlab.com | |
| Financial Indicators | ||
|---|---|---|
| Market Cap | 11.31 Cr. | |
| Earnings per share (EPS) | 2.33 | Trailing Twelve Months Ending 2021-03 |
| Price-Earning Ratio (PE) | 11.19 | Trailing Twelve Months Ending 2021-03 |
| Industry PE | 205.26 | Trailing Twelve Months Ending 2021-03 |
| Book Value / Share | 18.88 | Trailing Twelve Months Ending 2021-03 |
| Price to Book Value | 1.38 | Calculated using Price: 26.10 |
| Dividend Yield | 0.00 | Period Ending 2020-03 |
| No. of Shares Subscribed | 0.43 Cr. | 4,333,068 Shares |
| FaceValue | 10 | |
| Company Profile | ||
|
The Company was originally incorporated as partnership firm at New Delhi vide Partnership Agreement dated 15th Day of September, 2011 in the name of Dr. A Lalchandani Pathology Laboratories. Thereafter, the Partnership Firm was taken over by Dr Lalchandani Labs Limited incorporated under the provisions of Companies Act, 2013 vide certificate of Incorporation dated 2nd August, 2017 issued by the Registrar of Companies, Delhi vide agreement dated 31st August, 2017. The Company is formed to set up, engage, collaborate, acquire, purchase, maintain, open collection centres, conduct, manage, administer, own, run laboratories for the purposes of carrying out pathological investigations of various branches of Bio-Chemistry, Hematology, Histopathology, Microbiology, Electrophoresis, Virology, Cytology, other pathological Investigations and Immunoassay, Immuno-Histochemistry, Molecular Pathology, DNA & Genetic Testing etc. The company's customers include individual patients, hospitals and other healthcare providers and corporate customers. Diagnostic healthcare testing is an essential element in the delivery of healthcare services, as it provides healthcare service providers with useful information for the diagnosis and treatment of diseases. The Company is NABL Accredited Lab and has established 5 Self-Sufficient Labs and multiple collection centers within Delhi/NCR. Business area of the Company They are a provider of diagnostic and related healthcare tests and services in Delhi/NCR. Through their integrated network, they offer patients and healthcare providers a broad range of diagnostic and related healthcare tests and services for use in core testing, patient diagnosis and the prevention, monitoring and treatment of disease and other health conditions. Major Events and Milestones:
|
||
Company Profile
The Company was originally incorporated as partnership firm at New Delhi vide Partnership Agreement dated 15th Day of September, 2011 in the name of Dr. A Lalchandani Pathology Laboratories. Thereafter, the Partnership Firm was taken over by Dr Lalchandani Labs Limited incorporated under the provisions of Companies Act, 2013 vide certificate of Incorporation dated 2nd August, 2017 issued by the Registrar of Companies, Delhi vide agreement dated 31st August, 2017.
The Company is formed to set up, engage, collaborate, acquire, purchase, maintain, open collection centres, conduct, manage, administer, own, run laboratories for the purposes of carrying out pathological investigations of various branches of Bio-Chemistry, Hematology, Histopathology, Microbiology, Electrophoresis, Virology, Cytology, other pathological Investigations and Immunoassay, Immuno-Histochemistry, Molecular Pathology, DNA & Genetic Testing etc.
The company's customers include individual patients, hospitals and other healthcare providers and corporate customers. Diagnostic healthcare testing is an essential element in the delivery of healthcare services, as it provides healthcare service providers with useful information for the diagnosis and treatment of diseases. The Company is NABL Accredited Lab and has established 5 Self-Sufficient Labs and multiple collection centers within Delhi/NCR.
Business area of the Company
They are a provider of diagnostic and related healthcare tests and services in Delhi/NCR. Through their integrated network, they offer patients and healthcare providers a broad range of diagnostic and related healthcare tests and services for use in core testing, patient diagnosis and the prevention, monitoring and treatment of disease and other health conditions.
Major Events and Milestones:
| 1 Day |
|
-4.98% |
| 1 Week |
|
-4.98% |
| 1 Month |
|
+24.00% |
| 3 Month |
|
+1.22% |
| 6 Month |
|
+77.14% |
| 1 Year |
|
+163.83% |
| 2 Year |
|
+74.04% |
| 5 Year |
|
| 3 years | 2018-03 | 2019-03 | 2020-03 | |
| Return on Equity (%) | 8.11 | 9.85 | 6.01 | |
| Return on Capital Employed (%) | 10.06 | 12.57 | 9.17 | |
| Return on Assets (%) | 4.23 | 6.53 | 4.30 |
| Particulars | 3 years | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. |
| Shh. Funds | 3 | 8 | 9 | |
| Non Curr. Liab. | 1 | 1 | 2 | |
| Curr. Liab. | 2 | 1 | 2 | |
| Minority Int. | ||||
| Equity & Liab. | 6 | 10 | 12 | |
| Non Curr. Assets | 2 | 4 | 4 | |
| Curr. Assets | 4 | 6 | 8 | |
| Misc. Exp. not W/O | 0 | 0 | 0 | |
| Total Assets | 6 | 10 | 12 |
| Particulars | 3 years | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. |
| Net Sales | 3 | 5 | 6 | |
| Other Income | 0 | 0 | ||
| Total Income | 3 | 5 | 6 | |
| Total Expenditure | -2 | -4 | -5 | |
| PBIDT | 1 | 1 | 1 | |
| Interest | 0 | 0 | 0 | |
| Depreciation | 0 | 0 | 0 | |
| Taxation | 0 | 0 | 0 | |
| Exceptional Items | ||||
| PAT | 0 | 1 | 0 |
| Particulars | 3 years | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. |
| Cash Fr. Operatn. | 1 | 0 | 0 | |
| Cash Fr. Inv. | -1 | -2 | -1 | |
| Cash Fr. Finan. | 2 | 4 | 1 | |
| Net Change | 1 | 1 | 0 | |
| Cash & Cash Eqvt | 1 | 2 | 2 |
|
Mon, 12 Jul 2021
Outcome Of Board Meeting Dr Lalchandani Labs Limited wish to inform you that the Board of Directors of the Company at its meeting held today inter alia has transacted the following: 1. Statement showing the Audited Financial Statement Result for the half year and year ended 31st March 2021 along with Auditors Report on Audited Financial Results is also enclosed herewith and 2. In Compliance with Regulation 33(3)(d) of Listing Regulations and SEBI Circular No. CIR/CFD/CMD/56/2016 date 27th May 2016 we declare that report of Statutory Auditor is with unmodified opinion with respect to the Audited Financial Result of the Company for the half year and year ended 31st March 2021 is enclosed herewith. Kindly take the same on record and acknowledge. |
||||||||||||||
|
Mon, 12 Jul 2021
Audited Financial Results For The Half Year And Year Ended March 31 2021 Dr Lalchandani Labs Limited wish to inform you that the Board of Directors of the Company at its meeting held today inter alia has transacted the following: 1. Statement showing the Audited Financial Statement Result for the half year and year ended 31st March 2021 along with Auditors Report on Audited Financial Results is also enclosed herewith and 2. In Compliance with Regulation 33(3)(d) of Listing Regulations and SEBI Circular No. CIR/CFD/CMD/56/2016 date 27th May 2016 we declare that report of Statutory Auditor is with unmodified opinion with respect to the Audited Financial Result of the Company for the half year and year ended 31st March 2021 is enclosed herewith. Kindly take the same on record and acknowledge. |
||||||||||||||
|
Tue, 06 Jul 2021
Statement Of Investor Complaints For The Quarter Ended June 2021
|
| Tue, 27 Jul 2021 |
High Delivery Percentage
|
Close Crossing Last Week Low
|
Opening at High
|
Opening at Low
|
Closing Below Previous Low
|
Equities
M.F.
Sectors